ClinicalTrials.gg
TerminatedNCT01413074Updated Feb 17, 2026

Survival on Peritoneal Dialysis (PD) Versus Hemodialysis (HD) in China

An interventional study of Peritoneal Dialysis treatment and Hemodialysis treatment in End Stage Renal Disease, sponsored by Vantive Health LLC. Terminated at 7 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-17.

Sponsored by Vantive Health LLC (formerly part of Baxter Healthcare Corporation) · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
416
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 33 studies in Kidney Failure, Chronic by Baxter Healthcare Corporation — none open to participants now, none under way, none of them phase 3. Kidney Failure, Chronic · Baxter Healthcare Corporation.

Enrollment
2nd of 29
416 · median 43
Started
2011
with 2 others
No phase
22 of 33
none open now
Registered
14th of 33
by date

Among the 33 studies in Kidney Failure, Chronic by Baxter Healthcare Corporation, this one is the 2nd largest by enrollment of the 29 interventional ones that give a count, is one of 3 that started in 2011, is one of 22 with no phase, and was the 14th registered.

Kidney Failure, Chronic

2,115 studies on the registry are indexed under Kidney Failure, Chronic; 277 are open to participants now.

Browse Kidney Failure, Chronic studies →

Open to participants now

None of the 33 studies in Kidney Failure, Chronic by Baxter Healthcare Corporation is open now. The open studies under Kidney Failure, Chronic, anywhere →

Who these studies take

Of the 170 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 33 studies in Kidney Failure, Chronic by Baxter Healthcare Corporation as a file.
02

Study summary

Primary Objective: The primary objective is to prospectively assess and compare survival in subjects with End Stage Renal Disease (ESRD) randomized to Peritoneal Dialysis (PD) or Hemodialysis (HD) treatment.

Secondary Objectives: The secondary objectives are to prospectively assess and compare the following parameters in subjects receiving PD or HD treatment:

  • Technique failure
  • Cause of death
  • Comorbidity status at baseline and changes throughout the study
  • Change in residual renal function (RRF)
  • Dialysis adequacy (i.e., Kt/Vurea)
  • Change in blood pressure, hemoglobin, and S-phosphate
  • Change in nutritional status
  • Occurrence of bacterial and other infections
  • Hospitalization, including number, duration, and underlying reason(s)
  • Systemic inflammation as assessed by high-sensitivity C reactive protein (hs-CRP)
  • Quality of life (QOL)

Safety Objectives: To compare the nature and frequency of adverse events (AEs) and serious adverse events (SAEs), including abnormal laboratory test findings with clinical significance, in subjects receiving PD or HD treatment.

03

Conditions studied

  • End Stage Renal Disease

Keywords

  • End Stage Renal Disease
  • ESRD
  • Peritoneal Dialysis
  • PD
  • Hemodialysis
  • HD
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects of either sex, aged 18 years or older at time of randomization.
  2. Subjects diagnosed with ESRD ( [GFR] ≤ 15 mL/min/m2 body surface area [BSA]) and predicted by the investigator to need dialysis therapy within 10 weeks after the pre-screening period.
  3. Subjects who, as judged by the investigator, are able to comprehend the pre-defined, standardized, modality education program and have undertaken this education during the screening period.
  4. Subjects, or their legal representative, who, as judged by the investigator, are capable of being trained for home-based PD.
  5. Subjects, or their legal representative, who are able to understand and voluntarily sign an ICF.
  6. Subjects who are able to adhere to the study visit schedule and other protocol requirements.
  7. Subjects who are able to regularly visit a HD center for HD therapy (≥ 3 times per week).
  8. Subjects who, as judged by the investigator, are expected to remain on dialysis for at least 48 weeks.
  9. Subjects who have normal liver function, as judged by the investigator.
  10. Female subjects of who have a negative serum or urine pregnancy test at screening. Sexually active women of childbearing potential must agree to use adequate methods, as judged by the investigator, while in the study.

Exclusion criteria

Exclusion Criteria:

  1. Subjects who are positive.
  2. Subjects who have already received a permanent PD catheter or HD access that is intended for permanent use before receiving modality education or have already received permanent dialysis. Subjects are not excluded if an access is present within 4 weeks before screening for back-up purposes or for acute treatment of life-threatening uremic symptoms, electrolyte abnormalities, or fluid overload.
  3. Subjects who have a serious, uncontrolled medical disorder or active infection, which, as judged by the investigator, would jeopardize their ability to receive the prescribed dialysis treatment.
  4. Subjects who have dementia or a mental status that would significantly affect the subject's understanding of the Form (ICF).
  5. Subjects who are pregnant, intend to become pregnant during the study period, or are breast-feeding.
  6. Subjects with a history of drug (defined as illicit drug use) or alcohol (defined as regular or daily consumption of more than 4 alcoholic drinks per day) abuse in the 2 years before screening.
  7. Subjects who have previously received renal transplantation and are still being prescribed therapy.
  8. Subjects who are currently using or have used an product within five half-lives of the physiological action or 30 days, whichever is longer, before screening.
  9. Subjects who are unwilling or expected to be unable to fully comply with the visits and assessments required by the protocol.
  10. Subjects who have previously been randomized in this study.
  11. Subjects who are not eligible for either PD or HD, as judged by the investigator, due to:

    PD: documented extensive intra-peritoneal adhesions or other condition for PD.

    HD: severe cardiac instability or other condition contraindicated for HD.

  12. Subjects who have a serious or acute condition that, as judged by the investigator, would preclude participation in the study.
  13. Subjects who have a requiring chemotherapy or radiation therapy.
  14. Subjects undergoing temporary dialysis treatment between the screening visit and Day 1 that is expected to exceed 6 weeks in duration.
  15. Subjects who have a of less than 48 weeks.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
416 participants (actual)

Study arms

  • Active comparator
    ESRD patients receiving HD treatment

    no investigational drug involved. Only oberseve therapy treatment

    Other: Hemodialysis treatment

  • Experimental
    ESRD patients receiving PD treatment

    no investigational drug involved. Only oberseve therapy treatment

    Other: Peritoneal Dialysis treatment

Interventions

  • OtherPeritoneal Dialysis treatment

    PD treatment

  • OtherHemodialysis treatment

    HD treatment

06

What researchers measure

Primary outcomes

  1. Assess and compare survival or all cause mortality in subjects undergoing PD or HD treatment

    Time frame: 2-5 yrs.

Secondary outcomes

  1. Assess and compare technique failure

    Technique failure is defined as a change of dialysis modality (PD to HD, or HD to PD) or death. However, a temporary transfer, defined as ≤ 6 weeks duration and ≤ 2 occasions per any 52-week period, will not be considered technique failure. The use of both modalities within a 7-day period for more than 4 consecutive weeks will be considered technique failure. Technique failure will be monitored in two ways: modality failure including deaths and technique failure not including deaths.

    Time frame: 2-5 yrs.

  2. Residual Renal Function (RRF)

    RRF will be estimated if the subject's urine volume is ≥ 100 mL/24 h. RRF will be assessed by calculating GFR from a 24-h urine urea and creatinine collection and normalized to 1.73 m2 Body Surface Area. RRF will be measured at screening, visit 1 and every 12 weeks after visit 1 till the end of the study. Subjects who have a permanent modality transfer will be followed up for RRF (with the frequency of assessment determined by the modality they are switched to) until the end of the study, transplantation, stopping dialysis, lost to follow-up, or death.

    Time frame: 2-5 yrs

  3. Dialysis Adequacy

    In subjects receiving PD, dialysis adequacy (Kt/Vurea) will be assessed at 4 weeks (visit 2), 12 weeks (visit 4) and then every 12 weeks (±14 days) until the end of the study (±14 days). Kt/Vurea target for PD patients is ≥ 1.7 per week. Kt/Vurea target for HD patients is ≥ 1.2 per dialysis session. Subjects who have a permanent modality transfer will be followed up for Kt/Vurea (with the frequency of assessment determined by the modality they are switched to) until the end of the study, transplantation, stopping dialysis, lost to follow-up, or death.

    Time frame: 2-5 yrs.

  4. Co-morbidity Assessment

    The Charlson Comorbidity Index contains 19 categories of comorbidity which are primarily defined using ICD-9-CM diagnoses codes, as well as a few procedure codes. The overall comorbidity score reflects the cumulative increased likelihood of one-year survival; the higher the score, the more severe the burden of comorbidity. Every diagnosis and procedure code is analyzed to see if it falls within one of the 16 comorbid conditions. In this study, the comorbidity assessment will be measured at visit 1, every 24 weeks (±14 days) after visit 1 to visit 23, and at the end-of-study visit.

    Time frame: 2-5 yrs.

  5. Occurrence of Bacterial and Other Infections Infection rates

    Occurrence of bacterial and other infections infection rates, especially regarding exit sites and peritoneal, will be monitored for HD and PD patients.

    Time frame: 2-5 yrs.

  6. Hospitalization

    Hospitalization rates and duration for each underlying reason will be monitored for HD and PD patients.

    Time frame: 2-5 yrs.

  7. Transplantation Rate

    Kidney transplantation is the best outcome that a patient can expect. By default, a patient will be discontinued from the study after transplantation. Imbalance of the transplantation rate between HD and PD will be assessed. However, all patients will be followed to the end of the study to assess the primary endpoint which is all-cause mortality.

    Time frame: 2-5 yrs.

  8. Cause of Death

    Cause of deaths due to acute myocardial infarction (AMI), congestive heart failure (CHF), infection (except peritonitis), peritonitis, malnutrition, stroke, cardiovascular and non-cardiovascular causes, etc., will be monitored for HD and PD patients

    Time frame: 2-5 yrs.

  9. Change in Erythropoiesis-stimulating agent (ESA)

    Dose changes in ESA dose will affect patient's status for anemia control, and will be monitored for HD and PD patients.

    Time frame: 2-5 yrs.

  10. Change in blood pressure, hemoglobin, and S-phosphate

    Blood pressure, hemoglobin, and S-phosphate will be monitored for HD and PD patients.

    Time frame: 2-5 yrs.

  11. Subjective Global Assessment for Nutritional Status

    Subjective Global Assessment (SGA) is a technique to assess a patient's nutritional status. The SGA will be measured by one dedicated, trained physician per site at visit 1, every 24 weeks (±14 days) from visit 1 to visit 23, and at the end-of-study visit.

    Time frame: 2-5 yrs.

  12. Systemic inflammation as assessed by hs-CRP

    Scores of systemic inflammation will be assessed using high-sensitivity C reactive protein (hs-CRP). Hs-CRP will be assessed at visits 1, 4-23, and at the end-of-study visit.

    Time frame: 2-5 yrs.

  13. Quality of Life Quality of life (QOL)

    Quality of Life Quality of life (QOL) will be assessed using the EQ-5D-3L (European Quality of Life - 5 Dimensions - 3L translation), the KDQoL-SF (Kidney Disease Quality of Life Short Form) questionnaires, and the Karnofsky Index. QOL will be assessed at visit 1, every 24 weeks (±14 days) from visit 1 to visit 23, and at the end-of-study visit.

    Time frame: 2-5 yrs.

07

Study locations

7 sites
  • The First Affiliated Hospital , Sun Yet-Sen University
    Guangzhou, Guangdong 510080, China
  • Shanghai Changzheng Hospital
    Shanghai, Shanghai Municipality 200003, China
  • Ruijin Hospital,Shanghai Jiaotong University , School of Medicine
    Shanghai, Shanghai Municipality 200025, China
  • Huashan Hospital ,Fudan University
    Shanghai, Shanghai Municipality 200040, China
  • Renji Hospital , Shanghai Jiaotong University , School of Medicine
    Shanghai, Shanghai Municipality, China
  • The First Affiliated Hospital , Zhejiang University, School of Medicine
    Hangzhou, Zhejiang 310003, China
  • Hangzhou Hospital of Tranditional Chinese Medicine
    Hangzhou, Zhejiang 310007, China
08

References and documents

Publications

  • Ethier I, Hayat A, Pei J, Hawley CM, Johnson DW, Francis RS, Wong G, Craig JC, Viecelli AK, Htay H, Ng S, Leibowitz S, Cho Y. Peritoneal dialysis versus haemodialysis for people commencing dialysis. Cochrane Database Syst Rev. 2024 Jun 20;6(6):CD013800. doi: 10.1002/14651858.CD013800.pub2. PubMed 38899545 ↗
  • Quinn RR, Lam NN. Home Dialysis in North America: The Current State. Clin J Am Soc Nephrol. 2023 Oct 1;18(10):1351-1358. doi: 10.2215/CJN.0000000000000273. Epub 2023 Jul 31. PubMed 37523194 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2011, a primary completion of Dec 2013 and a completion of Dec 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2011
First posted
Aug 10, 2011
Start
Jun 2011
Primary completionActual
Dec 2013
CompletionActual
Dec 2013
Last update
Feb 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01413074
Lead sponsor
Vantive Health LLC
Responsible party
Sponsor
First posted
Aug 10, 2011
Start date
Jun 2011
Primary completion
Dec 2013
Completion
Dec 2013
Last update
Feb 17, 2026

Study contacts

Quian Jia-Qi, Prof.
principal investigator · Shanghai Jiao Tong University School of Medicine
Yu Xue-qing, Prof.
principal investigator · First Affiliated Hospital, Sun Yat-Sen University

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion